Astria Therapeutics (NASDAQ:ATXS) Sets New 1-Year High - Should You Buy?

Key Points

• Astria Therapeutics' stock reached a new 52-week high of $12.55, with a recent trading price of $12.48 and a market capitalization of $703.86 million.
• Recent analyst ratings show mixed opinions on the stock, with Jefferies downgrading it to "hold" with a target price of $13.00, while Evercore ISI maintains an "outperform" rating with a $26.00 target.
• Institutional investors own nearly 99% of Astria Therapeutics' stock, with notable increases in positions from firms like JPMorgan Chase & Co. and ADAR1 Capital Management.

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report)'s share price hit a new 52-week high on Friday . The stock traded as high as $12.55 and last traded at $12.48, with a volume of 85091 shares trading hands. The stock had previously closed at $12.38.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ATXS shares. Jefferies Financial Group lowered shares of Astria Therapeutics from a "buy" rating to a "hold" rating and decreased their target price for the company from $30.00 to $13.00 in a research report on Tuesday, October 14th. Evercore ISI restated an "outperform" rating and issued a $26.00 price target on shares of Astria Therapeutics in a research report on Wednesday, October 1st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Astria Therapeutics in a research note on Wednesday, October 8th. Wedbush set a $13.00 target price on shares of Astria Therapeutics and gave the stock a "neutral" rating in a research note on Wednesday, October 15th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Astria Therapeutics in a research note on Wednesday, August 13th. Three research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $25.00.

Astria Therapeutics Price Performance

The firm has a market capitalization of $703.86 million, a P/E ratio of -6.20 and a beta of 0.43. The stock's 50 day moving average is $7.99 and its two-hundred day moving average is $6.28.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.04. As a group, equities research analysts expect that Astria Therapeutics, Inc. will post -1.65 EPS for the current year.

Institutional Investors Weigh In On Astria Therapeutics

Several large investors have recently made changes to their positions in ATXS. JPMorgan Chase & Co. increased its position in shares of Astria Therapeutics by 4,607.1% during the second quarter. JPMorgan Chase & Co. now owns 1,696,071 shares of the biotechnology company's stock worth $9,091,000 after acquiring an additional 1,660,039 shares in the last quarter. ADAR1 Capital Management LLC increased its position in shares of Astria Therapeutics by 605.3% during the first quarter. ADAR1 Capital Management LLC now owns 641,690 shares of the biotechnology company's stock worth $3,427,000 after acquiring an additional 550,706 shares in the last quarter. Nantahala Capital Management LLC increased its position in shares of Astria Therapeutics by 59.7% during the second quarter. Nantahala Capital Management LLC now owns 1,069,530 shares of the biotechnology company's stock worth $5,733,000 after acquiring an additional 400,000 shares in the last quarter. Vestal Point Capital LP boosted its holdings in Astria Therapeutics by 8.2% during the second quarter. Vestal Point Capital LP now owns 4,522,000 shares of the biotechnology company's stock worth $24,238,000 after purchasing an additional 342,000 shares during the last quarter. Finally, Affinity Asset Advisors LLC acquired a new position in Astria Therapeutics during the second quarter worth $1,608,000. Institutional investors own 98.98% of the company's stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.